| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 200 | 96 | 9 | 8 | 4 | 4 | 9 | 12 | 4 | 11 | 3 | 3 | 7 | 2 | 5 | 4 | 10 | 5 | 5 | 8 | 9 | 16 | 9 | 7 | 5 | 7 | 3 | 3 | 3 | 5 | 6 | 8 |
| Expenses | 146 | 79 | 22 | 51 | 44 | 23 | 30 | 34 | 16 | 27 | 28 | 23 | 45 | 29 | 37 | 24 | 25 | 26 | 55 | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 |
| EBITDA | 54 | 17 | -13 | -42 | -39 | -19 | -22 | -22 | -12 | -15 | -25 | -20 | -38 | -27 | -32 | -20 | -15 | -22 | -49 | -26 | -22 | -11 | -40 | -26 | -27 | -48 | -38 | -43 | -50 | -76 | -101 | -44 |
| Operating Profit % | 24 % | 11 % | -936 % | -2,025 % | -2,635 % | -1,517 % | -999 % | -290 % | -994 % | -196 % | -1,764 % | -1,383 % | -2,118 % | -2,341 % | -733 % | -467 % | -595 % | -494 % | -1,720 % | -1,208 % | -737 % | -768 % | -1,885 % | -1,267 % | -3,023 % | -2,032 % | -2,435 % | -2,981 % | -2,714 % | -8,671 % | -3,678 % | -3,331 % |
| Depreciation | 6 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 47 | 11 | -14 | -44 | -40 | -20 | -23 | -23 | -13 | -17 | -26 | -22 | -39 | -28 | -34 | -21 | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 |
| Tax | 21 | 7 | 0 | -4 | -14 | -0 | 0 | 2 | -3 | -1 | -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 26 | 4 | -14 | -39 | -26 | -20 | -23 | -26 | -11 | -16 | -24 | -22 | -39 | -28 | -34 | -21 | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 |
| EPS in ₹ | 2.04 | 0.30 | -1.13 | -3.10 | -2.05 | -1.56 | -1.79 | -2.01 | -0.82 | -1.23 | -1.92 | -1.70 | -3.08 | -2.22 | -2.50 | -1.63 | -1.12 | -1.51 | -2.90 | -1.17 | -1.10 | -0.58 | -1.92 | -1.22 | -1.29 | -2.27 | -1.79 | -2.02 | -2.36 | -3.48 | -4.55 | -2.02 |
Suven Life Sciences
Suven Life Sciences
269.43
+16.86
(6.68%)
Market Cap
7,105.42 Cr
PE Ratio
-24.16
Volume
1,62,31,276.00
Day High - Low
276.00 - 255.41
52W High-Low
299.99 - 124.11
Key Fundamentals
Market Cap
7,105.42 Cr
EPS
-12.13
PE Ratio
-24.16
PB Ratio
11.29
Book Value
22.43
EBITDA
-284.51
Dividend Yield
0.00 %
Industry
Healthcare Sector
Healthcare Technology Return on Equity
-146.15
Debt to Equity
0.00
Actual
Company News
View All News
Suven Life Sciences published audited FY26 financial results ads in Andhra Prabha and Business Standard on May 14, 2026, per Regulation 47 of SEBI (LODR) Regulations, 2015.
Suven Life Sciences has scheduled a Board of Directors meeting on May 13, 2026, to consider and approve audited standalone and consolidated financial results for Q4 and FY26.
Suven Life Sciences clarifies price movement
Apr 08, 2026
Apr 08, 2026Suven Life Sciences states no material events pending disclosure under SEBI regulations, attributes recent price movements to market speculation following exchange surveillance queries.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
471.35 | #1 18,992.55 | 59.31 | #1 3,738.70 | 0.66 | 324 | -19.31 | 57.53 | |
511.40 | 12,314.92 | #1 30.67 | 3,510.50 | 19.14 | #1 349 | -32.23 | 52.26 | |
269.43 | #3 7,105.42 | #6 -24.16 | #8 7.11 | #8 -59.60 | #9 -276 | #4 -3.87 | 78.74 | |
453.10 | 2,023.97 | 35.09 | 322.30 | 0.22 | 41 | 112.87 | 45.52 | |
25.53 | 377.68 | 219.91 | 10.20 | #1 126.67 | 1 | -97.69 | 19.33 | |
84.49 | 168.28 | -78.60 | 47.50 | 17.87 | 0 | #1 2,300.00 | 57.54 | |
63.78 | 150.17 | -3.71 | 806.50 | 4.78 | -56 | 20.99 | 69.43 | |
16.43 | 23.70 | 33.09 | 84.00 | 5.00 | 2 | -83.33 | 22.28 | |
17.01 | 12.10 | -0.91 | 2.10 | -78.57 | -13 | -450.00 | 21.85 |
Growth Rate
Revenue Growth
-59.60 %
Net Income Growth
71.96 %
Cash Flow Change
-33.45 %
ROE
275.61 %
ROCE
268.61 %
EBITDA Margin (Avg.)
-
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 773 | 752 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Fixed Assets | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 77 |
| Current Assets | 477 | 428 | 492 | 570 | 281 | 66 | 103 | 67 | 252 | 257 | 76 | 547 |
| Capital Work in Progress | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 |
| Investments | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 0 |
| Other Assets | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 0 |
| Total Equity & Liabilities | 773 | 752 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Current Liabilities | 127 | 111 | 119 | 122 | 40 | 27 | 16 | 8 | 11 | 14 | 24 | 31 |
| Non Current Liabilities | 86 | 46 | 30 | 30 | 25 | 12 | 5 | 4 | 3 | 1 | 2 | 2 |
| Total Equity | 559 | 595 | 667 | 767 | 239 | 143 | 108 | 96 | 375 | 270 | 110 | 591 |
| Reserve & Surplus | 547 | 583 | 654 | 755 | 226 | 131 | 58 | 82 | 354 | 248 | 88 | 565 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 212 | -39 | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | 0 |
| Investing Activities | -110 | -39 | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 |
| Operating Activities | 143 | 68 | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -116 | -154 |
| Financing Activities | 179 | -68 | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Nov 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Jul 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 64.98 % | 64.98 % | 64.98 % | 64.98 % | 69.57 % | 69.57 % | 69.57 % | 69.57 % | 69.57 % | 69.57 % | 70.27 % | 70.27 % | 70.27 % | 70.27 % | 70.27 % | 67.43 % | 67.36 % | 67.36 % | 70.15 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.50 % | 0.54 % | 0.46 % | 0.45 % | 0.34 % | 0.34 % | 0.25 % | 0.59 % | 0.56 % | 1.18 % | 1.07 % | 0.91 % |
| DIIs | 0.21 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.13 % | 0.12 % | 0.11 % | 0.11 % | 0.08 % | 0.01 % | 0.12 % | 1.17 % | 1.17 % | 1.05 % | 1.06 % | 0.01 % | 0.02 % | 3.41 % | 3.39 % | 3.39 % | 4.62 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 33.92 % | 34.22 % | 33.19 % | 33.24 % | 28.69 % | 29.02 % | 27.37 % | 27.43 % | 22.98 % | 23.00 % | 23.29 % | 24.38 % | 24.05 % | 22.29 % | 22.66 % | 22.15 % | 22.31 % | 24.04 % | 23.17 % | 22.24 % | 22.25 % | 22.29 % | 19.45 % |
| Others | 5.87 % | 5.76 % | 6.79 % | 6.74 % | 6.31 % | 5.98 % | 7.52 % | 7.48 % | 7.34 % | 7.32 % | 7.06 % | 5.54 % | 5.72 % | 6.51 % | 5.46 % | 6.19 % | 6.04 % | 5.44 % | 5.95 % | 6.37 % | 5.82 % | 5.90 % | 4.87 % |
| No of Share Holders | 77,650 | 86,008 | 81,475 | 80,195 | 81,062 | 81,038 | 80,116 | 80,536 | 80,838 | 78,634 | 76,291 | 80,953 | 74,003 | 68,959 | 66,116 | 63,975 | 63,537 | 64,603 | 66,159 | 65,574 | 64,921 | 64,381 | 64,037 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 1 | 1.5 | 1.5 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 12.85 | 0.57 | 7.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Aug 2026 |  Annual General Meeting | NA | 25 Aug 2026 | 216.38 | 252.57 |
| 18 Oct 2022 |  Rights | 1:2 | 17 Oct 2022 | 64.87 | 68.00 |
| 02 Aug 2024 | Annual General Meeting | NA | 02 Aug 2024 | 113.45 | 143.05 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 131.40 | 121.40 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 133.25 | 122.20 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 131.05 | 153.07 |
| 05 Jun 2025 |  Extraordinary General Meeting | NA | 05 Jun 2025 | 153.07 | 234.35 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 268.80 | 233.20 |
| 22 Aug 2025 | Annual General Meeting | NA | 22 Aug 2025 | 153.07 | 234.35 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 197.55 | 187.15 |
| 29 Jan 2026 | Quarterly Result Announcement | NA | 29 Jan 2026 | 135.25 | 132.00 |
| 13 May 2026 | Quarterly Result Announcement | NA | 13 May 2026 | 205.65 | 216.38 |
Announcements
Clarification On Volume Movement Letter10 hrs ago
10 hrs agoClarification sought from Suven Life Sciences Ltd11 hrs ago
11 hrs agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Monitoring Agency Report5 days ago
5 days agoGrant Of Stock Options6 days ago
6 days agoOutcome Of The Meeting Of Board Of Directors Held On May 13 20266 days ago
6 days agoBoard Meeting Outcome for Outcome Of Board Meeting Of Suven Life Sciences Limited Held On May 13 20266 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoBoard Meeting Intimation for Consideration Of Audited Financial Results (Standalone And Consoldiated) For The Quarter And Financial Year Ended 31 March 2026.May 06, 2026
May 06, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 23, 2026
Apr 23, 2026Clarification On Price MovementApr 08, 2026
Apr 08, 2026Clarification sought from Suven Life Sciences LtdApr 07, 2026
Apr 07, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 09, 2026
Mar 09, 2026Board Meeting Outcome for ALLOTMENT OF 31768764 EQUITY SHARES OF THE COMPANY ON PREFERENTIAL BASISMar 06, 2026
Mar 06, 2026Announcement under Regulation 30 (LODR)-AllotmentMar 06, 2026
Mar 06, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 19, 2026
Feb 19, 2026Clarification On Price MovementFeb 06, 2026
Feb 06, 2026Clarification sought from Suven Life Sciences LtdFeb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 30, 2026
Jan 30, 2026Appointment of Company Secretary and Compliance OfficerJan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-AllotmentJan 29, 2026
Jan 29, 2026Board Meeting Outcome for Outcome Of The Board MeetingJan 29, 2026
Jan 29, 2026Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On Thursday January 29 2026Jan 29, 2026
Jan 29, 2026Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended December 31 2025 And Related MattersJan 22, 2026
Jan 22, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Jan 06, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 11, 2025
Dec 11, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Nov 12, 2025Un-Audited Standalone And Consolidated Financial Results For Quarter And Half-Year Ended 30Th September 2025Nov 11, 2025
Nov 11, 2025Board Meeting Intimation for To Consider And Approve Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half-Year Ended September 30 2025 And Related MattersNov 03, 2025
Nov 03, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 22, 2025
Aug 22, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Aug 13, 2025Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On August 13 2025Aug 13, 2025
Aug 13, 2025Board Meeting Intimation for Consider & Approve Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30 2025 And Related MattersAug 05, 2025
Aug 05, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 30, 2025
Jul 30, 2025Notice Of 36Th Annual General Meeting (AGM) Of The CompanyJul 30, 2025
Jul 30, 2025Reg. 34 (1) Annual Report.Jul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 24, 2025
Jul 24, 2025Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On Wednesday July 16 2025 - Allotment Of 9186490 Equity Shares Of The Company On Preferential Basis Upon Conversion 9186490 Fully Paid WarrantsJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Motilal Oswal BSE 1000 Index Fund Direct-Growth | 0.01% | 8 | 0.00% | 0.00% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.10% | 0 | 0.00% | 0.03% | |
 Quant Small Cap Fund Direct Plan-Growth | 0.33% | 0 | 0.00% | 0.09% |
Technical Indicators
RSI(14)
Neutral 75.02
ATR(14)
Volatile 13.83
STOCH(9,6)
Neutral 52.52
STOCH RSI(14)
Neutral 36.80
MACD(12,26)
Bearish -0.26
ADX(14)
Strong Trend 39.63
UO(9)
Bearish 56.34
ROC(12)
Uptrend And Accelerating 16.21
WillR(14)
Overbought -1.52
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
